Global Insulin Biosimilars Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
LPI (LP Information)' newest research report, the “Insulin Biosimilars Industry Forecast” looks at past sales and reviews total world Insulin Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin Biosimilars sales for 2023 through 2029. With Insulin Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Insulin Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin Biosimilars.
The global Insulin Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Insulin Biosimilars players cover Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Insulin Biosimilars market?
What factors are driving Insulin Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin Biosimilars market opportunities vary by end market size?
How does Insulin Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
LPI (LP Information)' newest research report, the “Insulin Biosimilars Industry Forecast” looks at past sales and reviews total world Insulin Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin Biosimilars sales for 2023 through 2029. With Insulin Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Insulin Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin Biosimilars.
The global Insulin Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Insulin Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Insulin Biosimilars players cover Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Rapid-Acting Biosimilars
- Long-Acting Biosimilars
- Premixed Biosimilars
- Type I Diabetes
- Type II Diabetes
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi S.A.
- Boehringer Ingelheim
- Eli Lilly & Co.
- Novo Nordisk A/S
- Biocon
- Geropharm
- Wockhardt
- Gan&Lee Pharmaceuticals
- The United Laboratories International
- Tonghua Dongbao Pharmaceutical
What is the 10-year outlook for the global Insulin Biosimilars market?
What factors are driving Insulin Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin Biosimilars market opportunities vary by end market size?
How does Insulin Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Insulin Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Insulin Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Insulin Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Insulin Biosimilars Segment by Type
2.2.1 Rapid-Acting Biosimilars
2.2.2 Long-Acting Biosimilars
2.2.3 Premixed Biosimilars
2.3 Insulin Biosimilars Sales by Type
2.3.1 Global Insulin Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Insulin Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Insulin Biosimilars Sale Price by Type (2018-2023)
2.4 Insulin Biosimilars Segment by Application
2.4.1 Type I Diabetes
2.4.2 Type II Diabetes
2.5 Insulin Biosimilars Sales by Application
2.5.1 Global Insulin Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Insulin Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Insulin Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL INSULIN BIOSIMILARS BY COMPANY
3.1 Global Insulin Biosimilars Breakdown Data by Company
3.1.1 Global Insulin Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Insulin Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Insulin Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Insulin Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Insulin Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Insulin Biosimilars Sale Price by Company
3.4 Key Manufacturers Insulin Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Insulin Biosimilars Product Location Distribution
3.4.2 Players Insulin Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INSULIN BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Insulin Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Insulin Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Insulin Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Insulin Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Insulin Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Insulin Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Insulin Biosimilars Sales Growth
4.4 APAC Insulin Biosimilars Sales Growth
4.5 Europe Insulin Biosimilars Sales Growth
4.6 Middle East & Africa Insulin Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Insulin Biosimilars Sales by Country
5.1.1 Americas Insulin Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Insulin Biosimilars Revenue by Country (2018-2023)
5.2 Americas Insulin Biosimilars Sales by Type
5.3 Americas Insulin Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Insulin Biosimilars Sales by Region
6.1.1 APAC Insulin Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Insulin Biosimilars Revenue by Region (2018-2023)
6.2 APAC Insulin Biosimilars Sales by Type
6.3 APAC Insulin Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Insulin Biosimilars by Country
7.1.1 Europe Insulin Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Insulin Biosimilars Revenue by Country (2018-2023)
7.2 Europe Insulin Biosimilars Sales by Type
7.3 Europe Insulin Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Insulin Biosimilars by Country
8.1.1 Middle East & Africa Insulin Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Insulin Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Insulin Biosimilars Sales by Type
8.3 Middle East & Africa Insulin Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Insulin Biosimilars
10.3 Manufacturing Process Analysis of Insulin Biosimilars
10.4 Industry Chain Structure of Insulin Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Insulin Biosimilars Distributors
11.3 Insulin Biosimilars Customer
12 WORLD FORECAST REVIEW FOR INSULIN BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Insulin Biosimilars Market Size Forecast by Region
12.1.1 Global Insulin Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Insulin Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Insulin Biosimilars Forecast by Type
12.7 Global Insulin Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi S.A.
13.1.1 Sanofi S.A. Company Information
13.1.2 Sanofi S.A. Insulin Biosimilars Product Portfolios and Specifications
13.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi S.A. Main Business Overview
13.1.5 Sanofi S.A. Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Insulin Biosimilars Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Eli Lilly & Co.
13.3.1 Eli Lilly & Co. Company Information
13.3.2 Eli Lilly & Co. Insulin Biosimilars Product Portfolios and Specifications
13.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eli Lilly & Co. Main Business Overview
13.3.5 Eli Lilly & Co. Latest Developments
13.4 Novo Nordisk A/S
13.4.1 Novo Nordisk A/S Company Information
13.4.2 Novo Nordisk A/S Insulin Biosimilars Product Portfolios and Specifications
13.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novo Nordisk A/S Main Business Overview
13.4.5 Novo Nordisk A/S Latest Developments
13.5 Biocon
13.5.1 Biocon Company Information
13.5.2 Biocon Insulin Biosimilars Product Portfolios and Specifications
13.5.3 Biocon Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Biocon Main Business Overview
13.5.5 Biocon Latest Developments
13.6 Geropharm
13.6.1 Geropharm Company Information
13.6.2 Geropharm Insulin Biosimilars Product Portfolios and Specifications
13.6.3 Geropharm Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Geropharm Main Business Overview
13.6.5 Geropharm Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Insulin Biosimilars Product Portfolios and Specifications
13.7.3 Wockhardt Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 Gan&Lee Pharmaceuticals
13.8.1 Gan&Lee Pharmaceuticals Company Information
13.8.2 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolios and Specifications
13.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Gan&Lee Pharmaceuticals Main Business Overview
13.8.5 Gan&Lee Pharmaceuticals Latest Developments
13.9 The United Laboratories International
13.9.1 The United Laboratories International Company Information
13.9.2 The United Laboratories International Insulin Biosimilars Product Portfolios and Specifications
13.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 The United Laboratories International Main Business Overview
13.9.5 The United Laboratories International Latest Developments
13.10 Tonghua Dongbao Pharmaceutical
13.10.1 Tonghua Dongbao Pharmaceutical Company Information
13.10.2 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolios and Specifications
13.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Insulin Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Insulin Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Insulin Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Insulin Biosimilars Segment by Type
2.2.1 Rapid-Acting Biosimilars
2.2.2 Long-Acting Biosimilars
2.2.3 Premixed Biosimilars
2.3 Insulin Biosimilars Sales by Type
2.3.1 Global Insulin Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Insulin Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Insulin Biosimilars Sale Price by Type (2018-2023)
2.4 Insulin Biosimilars Segment by Application
2.4.1 Type I Diabetes
2.4.2 Type II Diabetes
2.5 Insulin Biosimilars Sales by Application
2.5.1 Global Insulin Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Insulin Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Insulin Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL INSULIN BIOSIMILARS BY COMPANY
3.1 Global Insulin Biosimilars Breakdown Data by Company
3.1.1 Global Insulin Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Insulin Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Insulin Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Insulin Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Insulin Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Insulin Biosimilars Sale Price by Company
3.4 Key Manufacturers Insulin Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Insulin Biosimilars Product Location Distribution
3.4.2 Players Insulin Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INSULIN BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Insulin Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Insulin Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Insulin Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Insulin Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Insulin Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Insulin Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Insulin Biosimilars Sales Growth
4.4 APAC Insulin Biosimilars Sales Growth
4.5 Europe Insulin Biosimilars Sales Growth
4.6 Middle East & Africa Insulin Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Insulin Biosimilars Sales by Country
5.1.1 Americas Insulin Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Insulin Biosimilars Revenue by Country (2018-2023)
5.2 Americas Insulin Biosimilars Sales by Type
5.3 Americas Insulin Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Insulin Biosimilars Sales by Region
6.1.1 APAC Insulin Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Insulin Biosimilars Revenue by Region (2018-2023)
6.2 APAC Insulin Biosimilars Sales by Type
6.3 APAC Insulin Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Insulin Biosimilars by Country
7.1.1 Europe Insulin Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Insulin Biosimilars Revenue by Country (2018-2023)
7.2 Europe Insulin Biosimilars Sales by Type
7.3 Europe Insulin Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Insulin Biosimilars by Country
8.1.1 Middle East & Africa Insulin Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Insulin Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Insulin Biosimilars Sales by Type
8.3 Middle East & Africa Insulin Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Insulin Biosimilars
10.3 Manufacturing Process Analysis of Insulin Biosimilars
10.4 Industry Chain Structure of Insulin Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Insulin Biosimilars Distributors
11.3 Insulin Biosimilars Customer
12 WORLD FORECAST REVIEW FOR INSULIN BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Insulin Biosimilars Market Size Forecast by Region
12.1.1 Global Insulin Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Insulin Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Insulin Biosimilars Forecast by Type
12.7 Global Insulin Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi S.A.
13.1.1 Sanofi S.A. Company Information
13.1.2 Sanofi S.A. Insulin Biosimilars Product Portfolios and Specifications
13.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi S.A. Main Business Overview
13.1.5 Sanofi S.A. Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Insulin Biosimilars Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Eli Lilly & Co.
13.3.1 Eli Lilly & Co. Company Information
13.3.2 Eli Lilly & Co. Insulin Biosimilars Product Portfolios and Specifications
13.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eli Lilly & Co. Main Business Overview
13.3.5 Eli Lilly & Co. Latest Developments
13.4 Novo Nordisk A/S
13.4.1 Novo Nordisk A/S Company Information
13.4.2 Novo Nordisk A/S Insulin Biosimilars Product Portfolios and Specifications
13.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novo Nordisk A/S Main Business Overview
13.4.5 Novo Nordisk A/S Latest Developments
13.5 Biocon
13.5.1 Biocon Company Information
13.5.2 Biocon Insulin Biosimilars Product Portfolios and Specifications
13.5.3 Biocon Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Biocon Main Business Overview
13.5.5 Biocon Latest Developments
13.6 Geropharm
13.6.1 Geropharm Company Information
13.6.2 Geropharm Insulin Biosimilars Product Portfolios and Specifications
13.6.3 Geropharm Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Geropharm Main Business Overview
13.6.5 Geropharm Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Insulin Biosimilars Product Portfolios and Specifications
13.7.3 Wockhardt Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 Gan&Lee Pharmaceuticals
13.8.1 Gan&Lee Pharmaceuticals Company Information
13.8.2 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolios and Specifications
13.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Gan&Lee Pharmaceuticals Main Business Overview
13.8.5 Gan&Lee Pharmaceuticals Latest Developments
13.9 The United Laboratories International
13.9.1 The United Laboratories International Company Information
13.9.2 The United Laboratories International Insulin Biosimilars Product Portfolios and Specifications
13.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 The United Laboratories International Main Business Overview
13.9.5 The United Laboratories International Latest Developments
13.10 Tonghua Dongbao Pharmaceutical
13.10.1 Tonghua Dongbao Pharmaceutical Company Information
13.10.2 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolios and Specifications
13.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Insulin Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Insulin Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rapid-Acting Biosimilars
Table 4. Major Players of Long-Acting Biosimilars
Table 5. Major Players of Premixed Biosimilars
Table 6. Global Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 7. Global Insulin Biosimilars Sales Market Share by Type (2018-2023)
Table 8. Global Insulin Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 9. Global Insulin Biosimilars Revenue Market Share by Type (2018-2023)
Table 10. Global Insulin Biosimilars Sale Price by Type (2018-2023) & (USD/Unit)
Table 11. Global Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 12. Global Insulin Biosimilars Sales Market Share by Application (2018-2023)
Table 13. Global Insulin Biosimilars Revenue by Application (2018-2023)
Table 14. Global Insulin Biosimilars Revenue Market Share by Application (2018-2023)
Table 15. Global Insulin Biosimilars Sale Price by Application (2018-2023) & (USD/Unit)
Table 16. Global Insulin Biosimilars Sales by Company (2018-2023) & (K Units)
Table 17. Global Insulin Biosimilars Sales Market Share by Company (2018-2023)
Table 18. Global Insulin Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Insulin Biosimilars Revenue Market Share by Company (2018-2023)
Table 20. Global Insulin Biosimilars Sale Price by Company (2018-2023) & (USD/Unit)
Table 21. Key Manufacturers Insulin Biosimilars Producing Area Distribution and Sales Area
Table 22. Players Insulin Biosimilars Products Offered
Table 23. Insulin Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Insulin Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Insulin Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 28. Global Insulin Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Insulin Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Insulin Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Insulin Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 32. Global Insulin Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Insulin Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 35. Americas Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 36. Americas Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 38. Americas Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 39. Americas Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 40. APAC Insulin Biosimilars Sales by Region (2018-2023) & (K Units)
Table 41. APAC Insulin Biosimilars Sales Market Share by Region (2018-2023)
Table 42. APAC Insulin Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Insulin Biosimilars Revenue Market Share by Region (2018-2023)
Table 44. APAC Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 45. APAC Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 46. Europe Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 47. Europe Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 48. Europe Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 50. Europe Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 51. Europe Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Insulin Biosimilars
Table 59. Key Market Challenges & Risks of Insulin Biosimilars
Table 60. Key Industry Trends of Insulin Biosimilars
Table 61. Insulin Biosimilars Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Insulin Biosimilars Distributors List
Table 64. Insulin Biosimilars Customer List
Table 65. Global Insulin Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Insulin Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Insulin Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Insulin Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Insulin Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Insulin Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Insulin Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Insulin Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Sanofi S.A. Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 80. Sanofi S.A. Insulin Biosimilars Product Portfolios and Specifications
Table 81. Sanofi S.A. Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 82. Sanofi S.A. Main Business
Table 83. Sanofi S.A. Latest Developments
Table 84. Boehringer Ingelheim Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 85. Boehringer Ingelheim Insulin Biosimilars Product Portfolios and Specifications
Table 86. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 87. Boehringer Ingelheim Main Business
Table 88. Boehringer Ingelheim Latest Developments
Table 89. Eli Lilly & Co. Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 90. Eli Lilly & Co. Insulin Biosimilars Product Portfolios and Specifications
Table 91. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 92. Eli Lilly & Co. Main Business
Table 93. Eli Lilly & Co. Latest Developments
Table 94. Novo Nordisk A/S Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 95. Novo Nordisk A/S Insulin Biosimilars Product Portfolios and Specifications
Table 96. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 97. Novo Nordisk A/S Main Business
Table 98. Novo Nordisk A/S Latest Developments
Table 99. Biocon Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 100. Biocon Insulin Biosimilars Product Portfolios and Specifications
Table 101. Biocon Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 102. Biocon Main Business
Table 103. Biocon Latest Developments
Table 104. Geropharm Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 105. Geropharm Insulin Biosimilars Product Portfolios and Specifications
Table 106. Geropharm Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 107. Geropharm Main Business
Table 108. Geropharm Latest Developments
Table 109. Wockhardt Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 110. Wockhardt Insulin Biosimilars Product Portfolios and Specifications
Table 111. Wockhardt Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. Wockhardt Main Business
Table 113. Wockhardt Latest Developments
Table 114. Gan&Lee Pharmaceuticals Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 115. Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolios and Specifications
Table 116. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Gan&Lee Pharmaceuticals Main Business
Table 118. Gan&Lee Pharmaceuticals Latest Developments
Table 119. The United Laboratories International Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 120. The United Laboratories International Insulin Biosimilars Product Portfolios and Specifications
Table 121. The United Laboratories International Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 122. The United Laboratories International Main Business
Table 123. The United Laboratories International Latest Developments
Table 124. Tonghua Dongbao Pharmaceutical Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 125. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolios and Specifications
Table 126. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 127. Tonghua Dongbao Pharmaceutical Main Business
Table 128. Tonghua Dongbao Pharmaceutical Latest Developments
Table 1. Insulin Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Insulin Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rapid-Acting Biosimilars
Table 4. Major Players of Long-Acting Biosimilars
Table 5. Major Players of Premixed Biosimilars
Table 6. Global Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 7. Global Insulin Biosimilars Sales Market Share by Type (2018-2023)
Table 8. Global Insulin Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 9. Global Insulin Biosimilars Revenue Market Share by Type (2018-2023)
Table 10. Global Insulin Biosimilars Sale Price by Type (2018-2023) & (USD/Unit)
Table 11. Global Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 12. Global Insulin Biosimilars Sales Market Share by Application (2018-2023)
Table 13. Global Insulin Biosimilars Revenue by Application (2018-2023)
Table 14. Global Insulin Biosimilars Revenue Market Share by Application (2018-2023)
Table 15. Global Insulin Biosimilars Sale Price by Application (2018-2023) & (USD/Unit)
Table 16. Global Insulin Biosimilars Sales by Company (2018-2023) & (K Units)
Table 17. Global Insulin Biosimilars Sales Market Share by Company (2018-2023)
Table 18. Global Insulin Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Insulin Biosimilars Revenue Market Share by Company (2018-2023)
Table 20. Global Insulin Biosimilars Sale Price by Company (2018-2023) & (USD/Unit)
Table 21. Key Manufacturers Insulin Biosimilars Producing Area Distribution and Sales Area
Table 22. Players Insulin Biosimilars Products Offered
Table 23. Insulin Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Insulin Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Insulin Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 28. Global Insulin Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Insulin Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Insulin Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Insulin Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 32. Global Insulin Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Insulin Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 35. Americas Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 36. Americas Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 38. Americas Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 39. Americas Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 40. APAC Insulin Biosimilars Sales by Region (2018-2023) & (K Units)
Table 41. APAC Insulin Biosimilars Sales Market Share by Region (2018-2023)
Table 42. APAC Insulin Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Insulin Biosimilars Revenue Market Share by Region (2018-2023)
Table 44. APAC Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 45. APAC Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 46. Europe Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 47. Europe Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 48. Europe Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 50. Europe Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 51. Europe Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Insulin Biosimilars Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Insulin Biosimilars Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Insulin Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Insulin Biosimilars Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Insulin Biosimilars Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Insulin Biosimilars
Table 59. Key Market Challenges & Risks of Insulin Biosimilars
Table 60. Key Industry Trends of Insulin Biosimilars
Table 61. Insulin Biosimilars Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Insulin Biosimilars Distributors List
Table 64. Insulin Biosimilars Customer List
Table 65. Global Insulin Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Insulin Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Insulin Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Insulin Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Insulin Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Insulin Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Insulin Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Insulin Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Insulin Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Insulin Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Sanofi S.A. Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 80. Sanofi S.A. Insulin Biosimilars Product Portfolios and Specifications
Table 81. Sanofi S.A. Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 82. Sanofi S.A. Main Business
Table 83. Sanofi S.A. Latest Developments
Table 84. Boehringer Ingelheim Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 85. Boehringer Ingelheim Insulin Biosimilars Product Portfolios and Specifications
Table 86. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 87. Boehringer Ingelheim Main Business
Table 88. Boehringer Ingelheim Latest Developments
Table 89. Eli Lilly & Co. Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 90. Eli Lilly & Co. Insulin Biosimilars Product Portfolios and Specifications
Table 91. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 92. Eli Lilly & Co. Main Business
Table 93. Eli Lilly & Co. Latest Developments
Table 94. Novo Nordisk A/S Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 95. Novo Nordisk A/S Insulin Biosimilars Product Portfolios and Specifications
Table 96. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 97. Novo Nordisk A/S Main Business
Table 98. Novo Nordisk A/S Latest Developments
Table 99. Biocon Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 100. Biocon Insulin Biosimilars Product Portfolios and Specifications
Table 101. Biocon Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 102. Biocon Main Business
Table 103. Biocon Latest Developments
Table 104. Geropharm Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 105. Geropharm Insulin Biosimilars Product Portfolios and Specifications
Table 106. Geropharm Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 107. Geropharm Main Business
Table 108. Geropharm Latest Developments
Table 109. Wockhardt Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 110. Wockhardt Insulin Biosimilars Product Portfolios and Specifications
Table 111. Wockhardt Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. Wockhardt Main Business
Table 113. Wockhardt Latest Developments
Table 114. Gan&Lee Pharmaceuticals Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 115. Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolios and Specifications
Table 116. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Gan&Lee Pharmaceuticals Main Business
Table 118. Gan&Lee Pharmaceuticals Latest Developments
Table 119. The United Laboratories International Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 120. The United Laboratories International Insulin Biosimilars Product Portfolios and Specifications
Table 121. The United Laboratories International Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 122. The United Laboratories International Main Business
Table 123. The United Laboratories International Latest Developments
Table 124. Tonghua Dongbao Pharmaceutical Basic Information, Insulin Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 125. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolios and Specifications
Table 126. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 127. Tonghua Dongbao Pharmaceutical Main Business
Table 128. Tonghua Dongbao Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Insulin Biosimilars
Figure 2. Insulin Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Insulin Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Insulin Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Insulin Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rapid-Acting Biosimilars
Figure 10. Product Picture of Long-Acting Biosimilars
Figure 11. Product Picture of Premixed Biosimilars
Figure 12. Global Insulin Biosimilars Sales Market Share by Type in 2022
Figure 13. Global Insulin Biosimilars Revenue Market Share by Type (2018-2023)
Figure 14. Insulin Biosimilars Consumed in Type I Diabetes
Figure 15. Global Insulin Biosimilars Market: Type I Diabetes (2018-2023) & (K Units)
Figure 16. Insulin Biosimilars Consumed in Type II Diabetes
Figure 17. Global Insulin Biosimilars Market: Type II Diabetes (2018-2023) & (K Units)
Figure 18. Global Insulin Biosimilars Sales Market Share by Application (2022)
Figure 19. Global Insulin Biosimilars Revenue Market Share by Application in 2022
Figure 20. Insulin Biosimilars Sales Market by Company in 2022 (K Units)
Figure 21. Global Insulin Biosimilars Sales Market Share by Company in 2022
Figure 22. Insulin Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Insulin Biosimilars Revenue Market Share by Company in 2022
Figure 24. Global Insulin Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Insulin Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 27. Americas Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 28. APAC Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 29. APAC Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 30. Europe Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 31. Europe Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 34. Americas Insulin Biosimilars Sales Market Share by Country in 2022
Figure 35. Americas Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 36. Americas Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 37. Americas Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 38. United States Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Insulin Biosimilars Sales Market Share by Region in 2022
Figure 43. APAC Insulin Biosimilars Revenue Market Share by Regions in 2022
Figure 44. APAC Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 45. APAC Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 46. China Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Insulin Biosimilars Sales Market Share by Country in 2022
Figure 54. Europe Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 55. Europe Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 56. Europe Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 57. Germany Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Insulin Biosimilars Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 66. Egypt Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Insulin Biosimilars in 2022
Figure 72. Manufacturing Process Analysis of Insulin Biosimilars
Figure 73. Industry Chain Structure of Insulin Biosimilars
Figure 74. Channels of Distribution
Figure 75. Global Insulin Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 76. Global Insulin Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Insulin Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Insulin Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Insulin Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Insulin Biosimilars Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Insulin Biosimilars
Figure 2. Insulin Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Insulin Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Insulin Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Insulin Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rapid-Acting Biosimilars
Figure 10. Product Picture of Long-Acting Biosimilars
Figure 11. Product Picture of Premixed Biosimilars
Figure 12. Global Insulin Biosimilars Sales Market Share by Type in 2022
Figure 13. Global Insulin Biosimilars Revenue Market Share by Type (2018-2023)
Figure 14. Insulin Biosimilars Consumed in Type I Diabetes
Figure 15. Global Insulin Biosimilars Market: Type I Diabetes (2018-2023) & (K Units)
Figure 16. Insulin Biosimilars Consumed in Type II Diabetes
Figure 17. Global Insulin Biosimilars Market: Type II Diabetes (2018-2023) & (K Units)
Figure 18. Global Insulin Biosimilars Sales Market Share by Application (2022)
Figure 19. Global Insulin Biosimilars Revenue Market Share by Application in 2022
Figure 20. Insulin Biosimilars Sales Market by Company in 2022 (K Units)
Figure 21. Global Insulin Biosimilars Sales Market Share by Company in 2022
Figure 22. Insulin Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Insulin Biosimilars Revenue Market Share by Company in 2022
Figure 24. Global Insulin Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Insulin Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 27. Americas Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 28. APAC Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 29. APAC Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 30. Europe Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 31. Europe Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Insulin Biosimilars Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Insulin Biosimilars Revenue 2018-2023 ($ Millions)
Figure 34. Americas Insulin Biosimilars Sales Market Share by Country in 2022
Figure 35. Americas Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 36. Americas Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 37. Americas Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 38. United States Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Insulin Biosimilars Sales Market Share by Region in 2022
Figure 43. APAC Insulin Biosimilars Revenue Market Share by Regions in 2022
Figure 44. APAC Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 45. APAC Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 46. China Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Insulin Biosimilars Sales Market Share by Country in 2022
Figure 54. Europe Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 55. Europe Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 56. Europe Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 57. Germany Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Insulin Biosimilars Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Insulin Biosimilars Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Insulin Biosimilars Sales Market Share by Application (2018-2023)
Figure 66. Egypt Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Insulin Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Insulin Biosimilars in 2022
Figure 72. Manufacturing Process Analysis of Insulin Biosimilars
Figure 73. Industry Chain Structure of Insulin Biosimilars
Figure 74. Channels of Distribution
Figure 75. Global Insulin Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 76. Global Insulin Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Insulin Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Insulin Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Insulin Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Insulin Biosimilars Revenue Market Share Forecast by Application (2024-2029)
